MedTrace Logo

Safety and Efficacy of IQP-LH-101 in Postprandial Heartburn

NCT01718639 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 41

Last updated 2013-03-11

No results posted yet for this study

Summary

This study is a randomized, placebo-controlled, single-blind, three-way crossover clinical trial to evaluate safety and efficacy of IQP-LH-101 (tablet form and liquid form) in postprandial heartburn.

The null hypothesis is that there is no difference between IQP-LH-101 and the placebo in terms of efficacy for postprandial heartburn treatment.

Conditions

  • Postprandial Heartburn

Interventions

DEVICE

IQP-LH-101 tablet

Oral medical device in the form of a chewable tablet

DEVICE

IQP-LH-101 liquid

Oral medical device in the form of a liquid

OTHER

Placebo

Sponsors & Collaborators

  • InQpharm Group

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-10-31
Primary Completion
2013-03-31
Completion
2013-03-31

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01718639 on ClinicalTrials.gov